Report library

European Markets for Prosthetic Vascular Grafts

$3,850.00

Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.

July 1, 2013

U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

$3,750.00

The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.

July 1, 2013

United States, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.

January 1, 2013

U.S. Surgical Procedure Volumes

$4,750.00

This report presents the most common surgical procedures performed in the United States (U.S.) as well as an overview of the etiology and epidemiology of selected diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.

November 1, 2015

U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products

$3,750.00

Discoveries in molecular medicine in recent years have allowed researchers to study the genetic/chromosomal alterations that trigger the transformation of normal cells into malignant cells, which ultimately has led to the understanding that cancer—of which there are more than 100 forms—is a disease of the cellular genome.

March 1, 2013

France, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France

Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

$3,750.00

The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.

February 1, 2013

Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

Italy, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

Italy, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries

Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain

US Neurointerventional Devices Market, September 2016

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.

September 21, 2016

United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries

Oncology Pathways in the US – Friend or Foe for Pharma

$7,500.00

This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways.

July 31, 2015

Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.

January 26, 2016

Datamonitor Big Pharma Licensing Trends

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Accountable Care Organizations – What Impact on Pharma

$7,500.00

This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.

July 16, 2015

Immuno-Oncology Overview

$7,500.00

Immuno-oncology is an area of medicine that focuses on the development of therapies that improve the body’s ability to generate an immune response against cancer (Eggermont and Finn, 2012).

December 13, 2017

Biosimilars Market Access in the US

$2,995.00

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.

October 23, 2015

Datamonitor Malignant Melanoma Pricing and Reimbursement

Malignant Melanoma Pricing, Reimbursement and Access

$2,995.00

This strategy report focuses on Malignant Melanoma Pricing and Reimbursement including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU markets.

September 30, 2015

Current and Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Therapies

$4,750.00

Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).

March 1, 2013

Celgene

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

October 8, 2018

Allergan

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

October 10, 2018

Company Analysis: Gilead

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Mid Pharma Outlook

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

Company Analysis: UCB

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

Q2 2016 Earnings Previews

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

Orphan Drug Market Outlook to 2017

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.

Big Pharma Outlook 2015

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.

Company Analysis : AbbVie

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

July 15, 2020

Beraprost 314d

Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…

June 19, 2015

Company Analysis: AstraZeneca

PharmaVitae explores AstraZeneca’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Bayer

PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.

Dalvance

Dalvance is a second-generation, semi-synthetic lipoglycopeptide antibacterial compound of the same class as vancomycin. The drug inhibits the formation of, and disrupts the integrity of…

September 10, 2014

Company Analysis: Bristol-Myers Squibb

PharmaVitae explores Bristol-Myers Squibb’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Eli Lilly

PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

D/C/F/TAF

D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…

December 11, 2015

DCVAC/PCa

DCVAC/PCa is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells…

January 18, 2018

Company Analysis: Merck & Co

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Delafloxacin

Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.

September 10, 2014

Delzicol/Asacol HD

This product profile relates to the mesalamine franchise that covers Delzicol (mesalamine; Actavis), Asacol (mesalamine; Zeria/Kyowa Hakko Kirin), and Asacol HD (mesalamine; Actavis/Zeria)…

May 1, 2015

Company Analysis: Novo Nordisk

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.